National Comparative Audit of Blood Transfusion **NHS** Blood and Transplant

The Faculty of Intensive Care Medicine









2015 Audit of Patient Blood Management in Adults undergoing elective, scheduled surgery

Hospital Name

SUPPLEMENTARY INFORMATION REPORT

Your hospital participated in the 2015 National Comparative Audit of Patient Blood Management in Adults undergoing elective, scheduled surgery. Findings from this audit can help you to evaluate the quality of clinical staff's patient blood management practice in your hospital. This report provides detailed supporting information, such as the clinical characteristics of the audited patients.

- If you would like a summary of the key findings, please refer to the 'Key Findings' report.
- If you would like the full findings on how your hospital performed in relation to each of the audit standards, please refer to the '*Full Findings*' report.

Who is this report for?

It is recommended that copies of supplementary report is used by the clinical audit project team to provide additional information to support action planning as outlined in the key findings and full findings reports.

Local lead for this audit in your hospital: Name, Job Title, <u>name.surname@trust.nhs.net</u>

We wish to thank all those who have participated in the 2015 Audit of Patient Blood Management in Adults undergoing elective, scheduled surgery. We recognise that those giving up their valuable time have been

many and that this will inevitably have been on top of a heavy workload. This audit would clearly not be possible without their support. We are equally grateful to many colleagues for their valuable and constructive comments.

We would also like to acknowledge the support of the Royal College of Anaesthetists and the Quality Audit and Research Coordinators in Trusts who helped to identify anaesthetic trainees to support the data collection.

HOSPITALS THAT AGREED TO PILOT THE AUDIT

Barking, Havering & Redbridge University Hospitals NHS Trust; Bedford Hospital NHS Trust; Central Manchester Hospitals NHS Foundation Trust; Conquest Hospital; Eastbourne Hospital; Great Western Hospitals NHS Foundation Trust; Kettering General Hospital NHS Foundation Trust; North Bristol NHS Trust; Papworth Hospital NHS Foundation Trust; Queen Elizabeth Hospital, King's Lynn; South Tees Hospital NHS Foundation Trust; Taunton & Somerset Hospital; The Leeds Teaching Hospitals NHS Trust; University of South Manchester NHS Foundation Trust.

MEMBERS OF THE PROJECT GROUP

Kate Pendry	Joint Clinical Audit Lead
•	Consultant Haematologist, Central Manchester University Hospitals NHS
	Foundation Trust and NHS Blood and Transplant (NHSBT)
Shubha Allard	Joint Clinical Audit Lead
	Consultant Haematologist, Barts Health NHS Trust and NHSBT
Claire Atterbury	Transfusion Practitioner, Queen Elizabeth Hospital, King's Lynn
David Dalton	Project Officer, National Comparative Audit
Clare Denison	Patient Blood Management Practitioner, NHSBT
Katie Cowan	Patient Blood Management Practitioner, NHSBT
John Faulds	Blood Conservation Specialist, Royal Cornwall Hospital NHS Trust
John Grant-Casey	Programme Manager, National Comparative Audit
David Highton	Academic Clinical Fellow Anaesthesia/Critical Care National
	Hospital for Neurology & Neurosurgery
Alwyn Kotze	Consultant Anaesthetist, The Leeds Teaching Hospitals NHS Trust
Derek Lowe	Medical Statistician, Royal College of Physicians
Janardhan Rao	Consultant Orthopaedic Surgeon, Countess of Chester Hospital
Toby Richards	Consultant Vascular Surgeon, University College Hospital, London
Malcolm Robinson	Transfusion Laboratory Manager, Worthing Hospital
John Thompson	Consultant Vascular Surgeon, Royal College of Surgeons
David Whitaker	Consultant Anaesthetist, Royal College of Anaesthetist' representative on the
	National Blood Transfusion Committee
Alan White	Patient representative

For the Enhanced Report	Group
Michelle Collinson	AFFINITIE
Andrew Davies	AFFINITIE
Robbie Foy	AFFINITIE
Fabiana Lorencatto	AFFINITIE
Simon Stanworth	AFFINITIE

FOR CORRESPONDENCE, PLEASE CONTACT

John Grant-Casey, Programme Manager, National Comparative Audit of Blood Transfusion, FREEPOST (SCE 14677), BIRMINGHAM, B2 4BR

Email john.grant-casey@nhsbt.nhs.uk Tel: +44 (0)7720 275388 This report is intended to provide any additional, supporting information that may be of interest to clinical staff, but is not directly related to any of the audit standards. Why is this audit important?

Why is this audit important?	p.5
What does this audit aim to achieve?	р.6
What are the audit standards?	р.7
How was the audit conducted?	р.9
How was the audit data analysed?	p.10
Who took part in the audit?	p.11
What are the characteristics of the patients audited?	p.11
Patient Blood Management in the pre-operative period	p.13
How many days between listing and surgery?	
How many days between pre-operative assessment and s	urgery?
How was pre-operative anaemia investigated and manage	ed?
Pre-operative red cell transfusion	
How were patients taking oral anticoagulants and antiplat Patient Blood Management in theatre and recovery	elet agents managed pre-operatively? p.21
When was tranexamic acid used?	
Were topical haemostatic agent/sealants used?	
Was intra-operative cell salvage utilised?	
Was near patient testing of haemostasis utilised?	
Intra-operative allogeneic red cell transfusion	
Patient Blood Management in the Post-operative period	p.27
Post-operative cell salvage	
Post-operative Hb and Post-operative iron therapy	
Post-operative red cell transfusion	
What were the patient outcomes?	
Limitations of the audit	p. 31
Discussion	p.32
Abbreviations	p.32
Appendix 1: PBM Standard algorithms	p.33

Appendix 2: Audit tool	p.44
Appendix 3: Which hospitals participated?	P.60

Background

Patient Blood Management (PBM) is evidence-based medicine as applied to transfusion practice. Although effective PBM can lead to more appropriate use of the limited donated blood supply, transfusion avoidance is not the primary goal. Instead, PBM involves the application of current best evidence to optimise the care and outcomes of all patients who may require transfusion during the course of their care.¹

PBM offers the potential for a "win-win" of patient outcome improvements, cost savings, as well as the public health benefit of reduced demand on donors:²

- Transfusion is a life-saving intervention in certain situations where no alternative exists, e.g. exsanguination
 or marrow failure. However, in most clinical settings, red cell transfusions are administered to patients without
 active bleeding. Findings from a broad range of randomised controlled trials, including hip fracture surgery,
 have indicated no evidence of benefit for policies of liberal transfusions (or even in some reports, signals of
 harm to patients when outcomes are compared to patients receiving restrictive use of blood).² Choosing
 transfusion as first-line option for treating presumed tissue oxygen deficit in surgical practice may therefore
 be inappropriate.
- The donated blood supply is limited and vulnerable to demographic changes as well as the impact of infective pandemics.³⁻⁴ Though the surgical use of blood has decreased over time, ⁵ more can and should be done to limit demand on donors.
- Transfusion is more costly than commonly appreciated,⁶ and therefore minimising use of blood or consistent use of alternative management strategies would be attractive on financial grounds.⁷⁻⁸
- Transfusion, pre-operative anaemia and acute peri-operative anaemia all carry risk to patients⁹. PBM offers clinicians the opportunity to prevent their patients getting into situations where decisions must be made as to which of these risks is greater.

¹ Society for the Advancement of Blood Management. "Professional definition of PBM." Retrieved 28 December, 2014, from <u>www.sabm.org/</u>² Spahn, D. R., O. M. Theusinger and A. Hofmann (2012). "Patient blood management is a win-win: a wake-up call." Br J Anaesth 108: 889-892.

² Murphy, M.F., Waters J.H, Wood E.M and Yazer M.H. (2013): . "Transfusing blood safely and appropriately." BMJ, 347 .

³ Spahn, D. R., H. Moch, A. Hofmann and J. P. Isbister (2008). "Patient blood management: the pragmatic solution for the problems with blood transfusions." Anesthesiology 109: 951-953.

⁴ Seifried, E., H. Klueter, C. Weidmann, T. Staudenmaier, H. Schrezenmeier, R. Henschler, A. Greinacher and M. M. Mueller (2011). "How much blood is needed?" Vox Sang 100: 10-21.

⁵ Tinegate, H., Chattree, S., Iqbal, A., Plews, D., Whitehead, J., & Wallis, J. P. (2013). Ten-year pattern of red blood cell use in the North of England. Transfusion, *53*: 483-489.

⁶ Abraham, I. and D. Sun (2012). "The cost of blood transfusion in Western Europe as estimated from six studies." Transfusion 52: 1983-1988.

⁷ Spahn, D. R. (2010). "Anemia and patient blood management in hip and knee surgery: a systematic review of the literature." Anesthesiology 113: 482-495.

⁸ Ejaz, A., S. M. Frank, G. Spolverato, Y. Kim and T. M. Pawlik (2015). "Potential Economic Impact of Using a Restrictive Transfusion Trigger Among Patients Undergoing Major Abdominal Surgery." JAMA Surg 150: 625-630.

⁹ Kotzé, A., Harris, A., Baker, C., Iqbal, T., Lavies, N., Richards, T., Ryan K., Taylor C. & Thomas, D. (2015). British Committee for Standards in Haematology Guidelines on the Identification and Management of Pre-Operative Anaemia. British Journal of Haematology. DOI: 10.1111/bjh.13623

Despite many national¹⁰ and international¹¹⁻¹² recommendations being published in favour of PBM implementation, evidence suggests variability in uptake across the UK. A national survey of organisational arrangements indicated that only the minority of Trusts had adequate time in medical and nursing job plans for PBM, and that many Trusts did not have mechanisms for the reliable use of transfusion alternatives where appropriate.¹¹

References:

This audit was undertaken to document and understand clinical staff's current use of red cell transfusion and patient blood management approaches in adults undergoing elective, scheduled surgery in relation to 11 audit standards developed by the audit group. The audit is important at a number of levels:

- It provides national comparative data on PBM practice across the UK. Surgical blood use has decreased over time as a proportion of total blood use, but no national data is available on the breadth of PBM adoption across the country.
- For hospitals and individual clinicians, it provides data on how patients are managed along the surgical pathway. It is nowadays common for multiple clinicians to have input into one patient's care – aggregating data from multiple times (from referral to pre-assessment to surgery and post-operatively) may inform pathway design and help target improvement programmes.

The recommendations developed aim to achieve improved implementation of Patient Blood Management and red cell transfusion practice in surgical patients and consequently improved patient outcomes

PBM measures

The following table illustrates the PBM measures that are appropriate to the index operations. PBM measures are the standard of care for each procedure and ideally all aspects of PBM should have been attempted unless contraindicated or optional.

Timing of transfusion	ו	Procedure									
	Primary unilateral / bilateral total hip	Primary unilateral / bilateral and revision total knee replacement	Unilateral revision hip replacement	Surgery for #NOF	Colorectal resection for any indication	Open arterial surgery	artery bypass graft	Urological surgery: Cystectomy	Simple or complex hysterectomy		
	replacement						+/- CABG	Nephrectomy			
Pre operative	A	А	A	с	A	A	А	А	A		
	В	В	В		В	В	В	В	В		
	A	A	A	D	A	A	A	A	A		
	D	D	D		D	D	E	D	D		
Intra operative											
	G		F			F	F	G	G		
Post operative	А	А	Α	D	A	Α	А	А	А		

¹⁰ National Blood Transfusion Committee. (2014). "Patient Blood Management: An evidence-based approach to patient care." Retrieved 2 February, 2015, from http://www.transfusioncommittee. "Patient Blood Management: An evidence-based approach to patient care." Retrieved 2 February, 2015, from http://www.transfusionguidelines.org.uk/uk-transfusion-committees/national-blood-transfusion-committee/patient-blood-management.

¹¹ World Health Organisation. (2010). "Sixty-third world health assembly. Agenda Item 11.17: Availability, safety and quality of blood products WHA 63.12." Retrieved 9 September, 2015, from <u>http://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_R12-en.pdf.</u>

¹² Australian National Blood Authority. (2011). "Patient Blood Management Guidelines Module 2: Peri-operative." Retrieved 9 July, 2015, from http://www.blood.gov.au/system/files/documents/pbm-module-2.pdf

		-							· · · · · ·
	D	D	D		D	D	E	D	D
	G	н	F			F	F	G	G
	Н		н				н		
PBM Measu	ires Key								
A		Pre-operative a	Pre-operative anaemia optimisation						
В		Pre-operative management of patients on anticoagulants and antiplatelet agents							s
C		Pre-operative r	nanagen	nent of p	oatients o	n oral ar	nticoagulants		
D		Tranexamic aci	Tranexamic acid						
E		Tranexamic aci	Tranexamic acid/aprotinin						
F		Intra-operative	Intra-operative cell salvage						
G		Optional: Intra-	Optional: Intra-operative cell salvage						
н		Optional: Post-	operativ	e cell sa	vage				

Standard 1:	Pre-operative anaemia optimisation						
	Clinical staff must ensure that patients listed for elective major blood loss surgery have an Hb measured at least 14 days preoperatively and act upon results ¹³						
Standard 2:	Pre-operative transfusion indicated						
	Clinical staff should only prescribe a pre-operative transfusion in patients undergoing elective major blood loss surgery if the Hb is less than the defined Hb threshold for transfusion ¹⁴						
Standard 3:	Pre-operative transfusion indicated only if pre-operative anaemia optimisation has been attempted						
	Clinical staff should only prescribe a pre-operative transfusion in patients undergoing elective major blood loss surgery if the Hb is less than the defined Hb threshold for transfusion ² and pre-operative anaemia optimisation has been attempted						
Standard 4:	Pre-operative transfusion - single unit approach						
	For patients receiving a pre-operative transfusion, clinical staff should prescribe one unit of red cells at a time and re-check Hb before prescribing a further unit						

 $^{^{\}rm 13}$. Anaemia is defined as Hb of less than 130g/L in men less than 120g/L in women

¹⁴. Hb less than 70g/L in patients without acute coronary ischaemia or less than 80g/L in patients with acute coronary ischaemia

Standard 5:	Pre-operative anticoagulant and antiplatelet management
	 For patients undergoing elective major blood loss surgery who are taking oral anticoagulants and/or antiplatelet agents, clinical staff must stop the oral anticoagulant and/or antiplatelet agent(s) at least 5 days pre-operatively (unless there are good reasons to continue) and document the management plan in the case notes. For patients with fractured neck of femur taking warfarin, clinical staff should aim for an INR of less than 1.5 on the day before or the day of surgery
Standards 6&7:	Patient Blood Management in theatre and recovery
	Clinical staff should attempt at least one (PBM standard 6) or all (PBM standard 7) appropriate patient blood management measures in patients who receive a transfusion during major blood loss surgery
Standard 8:	Post-operative transfusion indicated
	In patients who do not have active post-operative bleeding, clinical staff should only prescribe a transfusion if the Hb is less than the defined Hb threshold for transfusion ²
Standard 9:	Post-operative transfusion - single unit approach
	For patients receiving a post-operative transfusion, clinical staff should prescribe one unit of red cells at a time and re-check Hb before prescribing a further unit unless the patient has active bleeding
Standards 10&11	: Patient Blood Management in the post-operative period
	Clinical staff should attempt at least one (PBM standard 10) or all (PBM standard 11)

Clinical staff should attempt at least one (PBM standard 10) or all (PBM standard 11) appropriate patient blood management measures in patients who receive a transfusion following major blood loss surgery

Analysis of compliance with standards was undertaken using a series of algorithms as shown in Appendix 1 Overall performance against standards

Algorithm	Standard MET	Standard NOT MET	EXCLUDED	INSUFFICIENT DATA	% standard MET*	YOUR HOSPITAL: % standard MET*
PBM1	1305	1531	1044	17	46%	67% (2/3)
PBM2	28	214	3529	126	12%	0% (0/2)
РВМЗ	3	129	3655	110	2%	0% (0/0)
PBM4	71	182	3529	115	28%	0% (0/2)
PBM5	340	201	3279	77	63%	0% (0/2)
PBM6	661	134	3027	75	83%	0% (0/0)
PBM7	133	675	3027	62	16%	0% (0/1)
PBM8	669	2088	996	144	24%	22% (4/18)
РВМ9	920	1492	1358	127	38%	13% (2/16)
PBM10	1714	312	1748	123	85%	50% (2/4)
PBM11	175	1910	1748	64	8%	0% (0/4)

Patient Blood Management performance by type of procedure

	Primary unilateral total hip replacement	Primary bilateral total hip replacement	Primary unilateral total knee replacement	Primary bilateral total knee replacement	Unilateral revision hip replacement	Unilateral revision knee replacement	Colorectal resection for any indication
PBM1	57% (346/610)	50% (15/30)	63% (215/341)	70% (19/27)	50% (128/258)	52% (35/67)	27% (81/300)
PBM2	0% (0/14)	-	0% (0/1)	-	11% (1/9)	0% (0/2)	18% (7/40)
PBM3	0% (0/15)	-	0% (0/1)	-	0% (0/9)	0% (0/2)	2% (1/42)
PBM4	33% (5/15)	-	0% (0/1	-	33% (3/9)	0% (0/2)	19% (8/42)
PBM5	67% (48/72)	25% (1/4)	68% (21/31)	-	47% (20/43)	70% (7/10)	74% (23/31)
PBM6	92% (68/74)	86% (6/7)	92% (12/13)	-	91% (77/85)	100% (10/10)	38% (42/110)
PBM7	34% (26/77)	14% (1/7)	42% (5/12)	0% (0/1)	9% (8/86)	0% (0/10)	3% (3/116)
PBM8	16% (79/487)	14% (3/22)	18% (51/279)	16% (4/25)	23% (37/163)	12% (7/57)	30% (45/151)
PBM9	31% (144/460)	29% (5/17)	27% (72/264)	39% (9/23)	46% (63/138)	21% (11/53)	34% (44/128)
PBM10	89% (435/491)	86% (19/22)	91% (262/287)	100% (25/25)	87% (146/167)	91% (53/58)	35% (53/153)
PBM11	0.4% (2/519)	18% (4/22)	1% (4/292)	16% (4/25)	17% (29/169)	13% (7/56)	0% (0/159)

	Open arterial surgery	Primary CABG	Valve replacement +/- CABG	Simple or complex hysterectomy	Cystectomy	Nephrectomy	# neck of femur (arthroplasty)
PBM1	32% (51/157)	29% (34/116)	43% (183/421)	38% (129/342)	38% (14/37)	42% (55/130)	-
PBM2	20% (2/10)	0% (0/1)	0% (0/2)	14% (4/29)	0% (0/3)	33% (4/12)	8% (10/118)
PBM3	10% (1/10)	0% (0/1)	0% (0/4)	3% (1/32)	0% (0/4)	0% (0/12)	-

PBM4	36% (4/11)	0% (0/1)	67% (2/3)	11% (3/28)	25% (1/4)	8% (1/12)	35% (44/124)
PBM5	68% (38/56)	78% (35/45)	61% (80/132)	58% (7/12)	0% (0/1)	72% (13/18)	55% (47/86)
PBM6	90% (55/61)	96% (43/45)	99% (182/184)	83% (90/108)	82% (9/11)	78% (54/69)	72% (13/18)
PBM7	5% (3/62)	22% (10/45)	28% (51/181)	8% (9/112)	8% (1/13)	4% (3/68)	72% (13/18)
PBM8	33% (28/85)	47% (42/90)	38% (110/292)	40% (83/209)	28% (7/25)	33% (21/64)	19% (151/798
РВМ9	47% (32/68)	87% (55/63)	83% (171/206)	24% (36/151)	24% (5/21)	41% (21/51)	32% (247/761
PBM10	85% (73/86)	98% (89/91)	97% (292/300)	83% (165/198)	83% (20/24)	82% (50/61)	51% (32/63)
PBM11	1% (1/90)	23% (21/91)	22% (67/299)	0% (0/211)	8% (2/25)	3% (2/64)	51% (32/63)

METHODS

The audit was conducted on cases occurring during a 3 month period between February and April 2015.

Hospital selection and response

All hospitals/Trusts in England, Scotland, Wales, Northern Ireland and Republic of Ireland where transfusions are administered to adult surgical patients were invited to take part. Data were submitted by Trusts as a whole and by individual hospitals. The term hospital is used throughout this report to refer to the entity engaged in the audit process at each hospital

Case selection and quotas

Participating hospitals were asked to collect data on all consecutive cases of patients who had undergone any of the audit index operations and received transfusion pre-operatively and/or intra-operatively and/or up to 7 days post-operatively. Up to a maximum of 70 cases per hospital were collected from patients operated on during the period 1st Feb 2015 to 30th April 2015. The majority of procedures were elective and scheduled, however patients undergoing surgery for fractured neck of femur were also included to ensure that meaningful numbers of cases were collected for the audit.

A list of OPCS4 codes was provided for the index operations (table below) and hospitals were asked to liaise with their Informatics Department to collect a list of patients who had undergone one of these procedures. Transfused cases were identified with reference to laboratory data.

Procedure Descriptions	OPCS Codes
Primary unilateral total hip replacement	W37.1, W38.1, W39.1 with a Z94.2, Z94.3 or Z94.4
Primary bilateral total hip replacement	W37.1, W38.1, W39.1 with a Z94.1
Primary unilateral total knee replacement	W40.1, W41.1, W42.1 with a Z94.2, Z94.3 or Z94.4
Primary bilateral total knee replacement	W40.1, W41.1, W42.1 with a Z94.1
Unilateral revision hip replacement	W37.3, W37.4, W38.3, W38.4, W39.3 with a Z94.2, Z94.3, Z94.4
Unilateral revision knee replacement	W40.3, W40.4, W41.3, W41.4, W42.3 with a Z94.2, Z94.3, Z94.4
Colorectal resection for any indication (open or laparoscopic)	H29, H33 H048; H061; H062; H099; H103; H108; H41.1

Open arterial surgery e.g.: scheduled ((nonruptured) aortic aneurysm repair, infrainguinal, femoropopliteal or distal bypass)	L19.3 - L19.6, L21.3 - L21.6, L49, L51, L57, L59
Primary coronary artery bypass graft	K40 - K45 (excluding K44.2, K45.6) in any procedural position
Valve replacement +/- CABG	K25 - K29 (INCLUSIVE)
Simple or complex hysterectomy	Q07 - Q08 (INCLUSIVE)
Cystectomy	M34.3, M34.4, M35.9
Nephrectomy	M02.1. M02.3, M02.5, M03.1, M03.9
# neck of femur (arthroplasty)	W19.1, W24.1, W46.1 to W46.9, W47.1 to W47.9, W48.1 to W48.9

Data entry, cleaning and validation

The audit data from the transfusion episode was entered via a web-based audit tool specifically designed for the purpose although data could be collected on a paper proforma (see appendix 2). Submitted audit data was collated by the audit Programme Manager after the closing date for data entry. Because no patient identifiable data is recorded on the web-based audit tool, hospital auditors were advised to keep an audit linkage record to assist in review of cases and validation of data. Algorithms were developed to analyse whether the standards were met using the definitions outlined below (see appendix 1). There was some post-hoc analysis of the free text answers where indicated.

Definition of Patient Blood Management Measures

Pre-operative Anaemia optimisation

Patients with iron deficiency anaemia identified pre operatively and treated with oral or intravenous iron (anaemia defined as Hb less than 120g/L in females and less than 130g/L in males) at least 14 days before surgery; iron deficiency was defined as ferritin less than 30 μ g/L, transferrin saturation less than 20% if no ferritin performed or MCV <78fl if no ferritin or transferrin saturation performed. There was no expectation for optimisation of other forms of anaemia or for optimisation of anaemia in patients with fractured neck of femur.

Pre-operative management of patients on anticoagulants and antiplatelet agents

Excluding those having surgery for fractured neck of femur, patients on oral anticoagulants (e.g. warfarin or novel oral anticoagulants as listed in the audit tool) must have the oral anticoagulant discontinued at least 5 days preoperatively. Patients on antiplatelet agents (dual antiplatelet therapy, clopidogrel, ticagrelor, prasugrel*) must have the drug(s) discontinued at least 5 days pre-operatively unless there are good clinical reasons for continuation, that is: coronary artery stent within last 12 months, active ischaemic heart disease in patients undergoing bypass surgery.

*It is acceptable to continue low dose aspirin therapy peri-operatively.

For fractured neck of femur patients on warfarin: anticoagulation should be managed so that INR is <1.5 on day of or day before surgery.

Intra-operative cell salvage

In appropriate types of surgery, cell salvage should be set up and an attempt made to collect; standard is still met if not enough collected for return. Exceptions: active sepsis, malignancy, contaminated field.

Post-operative cell salvage

This is considered optional and can be washed red cells or reinfused shed blood.

Participation and sample size

A total of 3925 audit records were received, after extending the deadline for submission by an extra week. A total of 28 duplicate records were identified and removed from the dataset leaving 3897 cases for analysis, submitted by 190 hospitals (median of 18 cases per hospital, IQR 9-30, range 1-69). The list of participating hospitals is presented in Appendix 3.

The audit period specified for including operations was February to April 2015 inclusive, with 1783 cases in February, 1314 cases in March and 683 cases in April. Details were also received for a further 105 operations (from 46 hospitals) that fell outside the audit period; these were included in the analysis, with 72 cases in January, 30 cases in May, 2 in June and 1 in July. Also included were 12 operations for which the date of surgery was not stated.

NHS England/N Ireland/Scotland/Wales: 3628 cases from 155 hospitals, median 21, IQR 13-32, range 1-69.

Independent Hospitals: 165 cases from 28 hospitals, median 6, IQR 2-10, range 1-12.

Republic of Ireland: 104 cases from 7 hospitals, median 16, range 4-26.

Your hospital: 23 cases

The national results in this report are derived from all 3897 cases from 190 hospitals.

What are the characteristics of the patients audited?

Patient demographics

Of the 3897 cases, gender was known for 3873 and 65% (2519) were female and 35% were male (1354). The median age was 76 years (IQR 66-84). The breakdown by gender and age group for your hospital is shown in the tables below.

Gender

	National	Your hospital
Gender known	3873	
Female	65% (2519)	20
Male	35% (1354)	3

Patient age

National	Your
	hospital

I.		
Age known	3891	23
<55	12% (449)	
55-64	10% (403)	
65-74	23% (908)	
75-84	30% (1182)	
≥85	24% (949)	
Median (IQR)	76 (66-84)	Median: 80

The median age of patients undergoing the various procedures is shown in the table below (national figures). Note that the median age for patients with fractured neck of femur was 86 years (IQR 80-91) and these accounted for 27%


of the patients (1044). It is likely that the large number of fractured neck of femur patients accounts for the larger percentage of females.

TYPE OF PROCEDURE	Median (IQR) age
Primary unilateral total hip replacement	77 (67-83), n=608
Primary bilateral total hip replacement	74 (66-85) <i>,</i> n=30
Primary unilateral total knee replacement	76 (68-82), n=339
Primary bilateral total knee replacement	71 (60-82), n=27
Unilateral revision hip replacement	75 (67-82), n=258
Unilateral revision knee replacement	73 (65-79), n=67
Colorectal resection for any indication	71 (61-79), n=300
Open arterial surgery	73 (65-78), n=157
Primary coronary artery bypass graft	69 (63-76), n=116
Valve replacement +/- CABG	73 (66-79), n=423
Simple or complex hysterectomy	51 (44-65) <i>,</i> n=340
Cystectomy	68 (59-78), n=37
Nephrectomy	68 (57-74), n=130
# neck of femur (arthroplasty)	86 (80-91), n=1044
Procedure not stated	78 (73-86), n=15

When was blood transfused?

The majority of transfusions occurred during the postoperative period. See the chart and table below for national figures

Summary of pre-op, intra-op and post-op red blood cell transfusions (including number of units transferred)



	National
Pre-operative	277
Intra-operative	982
Post-operative	2878

Opportunities for PBM in the pre-operative period include pre-operative anaemia identification and optimisation and appropriate management of patients taking anticoagulants and antiplatelet therapy.

It is important that there is enough time for a full patient assessment and development of a management plan in advance of surgery so that the patient is optimised at the time of surgery.

The following section gives detailed information about the timings between listing and surgery and pre-operative assessment and surgery.

How many days between listing and date of surgery?

Excluding patients with fractured neck of femur, 94% (2678/2853) of patients had a listing date.

The median (IQR) time from listing to surgery was 42 days (13-93).

There was considerable variation between the different procedures. As expected, there was a longer time between listing and actual date of surgery for elective orthopaedic surgery compared to coronary artery bypass surgery or types of surgery associated with malignancy as shown for the national dataset in the table below

TYF	PE OF PROCEDURE	% (N) listed	Days between listing and surgery: Median (IQR)
	Primary unilateral total hip replacement	94% (572/610)	64 (20-115), n=571
	Primary bilateral total hip replacement	97% (29/30)	61 (13-99), n=28
	Primary unilateral total knee replacement	94% (322/341)	92 (50-144), n=322
	Primary bilateral total knee replacement	100% (27/27)	105 (36-137), n=27
	Unilateral revision hip replacement	95% (245/258)	48 (9-102), n=245
	Unilateral revision knee replacement	97% (65/67)	50 (19-102), n=65
	Colorectal resection for any indication	94% (281/300)	18 (8-36), n=280
	Open arterial surgery	94% (148/157)	23 (5-59), n=148
	Primary coronary artery bypass graft	89% (103/116)	12 (5-43), n=103
	Valve replacement +/- CABG	91% (384/423)	42 (12-90), n=384
	Simple or complex hysterectomy	96% (329/342)	28 (14-71), n=329
	Cystectomy	92% (34/37)	32 (14-53), n=34
	Nephrectomy	98% (127/130)	26 (12-42), n=127
	# neck of femur (arthroplasty)	0% (0/1044)	-
Pro	cedure not stated	80% (12/15)	6 (0-64), n=12

How many days between pre-operative assessment and surgery?

Excluding patients with fractured neck of femur, 92% (2638/2853) of patients had a pre-operative assessment. In your hospital this was 50% (2/4).

The table below shows the national proportions of those having a pre-operative assessment.

	NATIONAL
TYPE OF PROCEDURE	% (N) with pre-
TTPE OF PROCEDORE	operative
	assessment

Primary unilateral total hip replacement	90% (533/595)
Primary bilateral total hip replacement	83% (25/30)
Primary unilateral total knee replacement	98% (329/337)
Primary bilateral total knee replacement	100% (27/27)
Unilateral revision hip replacement	82% (211/257)
Unilateral revision knee replacement	88% (58/66)
Colorectal resection for any indication (open or laparoscopic)	82% (244/296)
Open arterial surgery	73% (114/156)
Primary coronary artery bypass graft	84% (97/115)
Valve replacement +/- CABG	80% (337/422)
Simple or complex hysterectomy	93% (315/340)
Cystectomy	80% (28/35)
Nephrectomy	91% (118/130)
# neck of femur (arthroplasty)	19% (192/1031)
Procedure not stated	83% (10/12)

Days from pre-operative assessment to surgery

Nationally the median (IQR) time from assessment to surgery was 17 days (7-44) in the 2608 cases where the date was known.

In your hospital the median was 25 days in the 2 cases where the date was known.

The table below shows the timings for pre-operative assessment for different types of surgery:

ТҮР	E OF PROCEDURE	NATIONAL Days between assessment and surgery: Median (IQR)
	Primary unilateral total hip replacement	25 (13-59), n=529
	Primary bilateral total hip replacement	32 (15-93), n=24
	Primary unilateral total knee replacement	28 (15-76), n=325
	Primary bilateral total knee replacement	26 (13-47), n=27
	Unilateral revision hip replacement	22 (10-48), n=211
	Unilateral revision knee replacement	20 (7-39), n=57
	Colorectal resection for any indication (open or laparoscopic)	11 (6-21), n=240
	Open arterial surgery e.g.: scheduled (nonruptured) aortic aneurysm repair, infrainguinal, femoropopliteal or distal bypass	19 (6-62), n=111
	Primary coronary artery bypass graft	8 (1-42), n=95
	Valve replacement +/- CABG	21 (7-61), n=333
	Simple or complex hysterectomy	13 (7-28), n=313
	Cystectomy	15 (9-26), n=28
	Nephrectomy	13 (7-23), n=117
	# neck of femur (arthroplasty)	0 (0-1), n=188
	Procedure not stated	9 (2-36), n=10

		National	Your hospital
Pre	-operative assessment within 0-28 days before surgery:	66% (1711/2608)	100% (2/2)
Rea	ason:*		
	Emergency Trauma	11% (188)	0
	Cancer surgery	11% (187)	0
	Other urgent	15% (260)	0
	Waiting list initiative	1% (11)	0
	Routine practice	19% (326)	0
	Other non-urgent	0.4% (6)	0
	No reason given/not known	43% (733)	2

Note that the reason was not known in 43% or was routine practice in 19% of cases nationally. There were good clinical reasons for a short time period in 37% of cases. More detail is given in the table below broken down by the different procedures at national level.

	If pre-operative assessment took place < 28 days before surgery what was the reason? *								
ТҮР	PE OF PROCEDURE	Emergency trauma	Cancer surgery	Other urgent	Waiting list initiative	Routine practice	Other nonurgent	No reason given/not known	Total
	Primary unilateral total hip replacement	7	4	28	5	101	-	149	294
	Primary bilateral total hip replacement	-	-	-	-	4	-	6	10
	Primary unilateral total knee replacement	-	1	3	3	49	1	108	165
	Primary bilateral total knee replacement	-	-	-	-	5	-	9	14
	Unilateral revision hip replacement	3	-	29	-	32	3	60	127
	Unilateral revision knee replacement	1	-	11	-	10	1	15	38
	Colorectal resection for any indication (open or laparoscopic)	-	74	30	-	20	-	71	195
	Open arterial surgery e.g.: scheduled (non- ruptured) aortic aneurysm repair, infrainguinal femoropopliteal or distal bypass	-	-	33	-	5	-	29	67
	Primary coronary artery bypass graft	-	-	43	-	2	-	23	68
	Valve replacement +/- CABG	-	1	43	1	36	1	102	184
	Simple or complex hysterectomy	-	67	23	2	45	-	104	241
	Cystectomy	-	7	2	-	8	-	6	23
	Nephrectomy	-	33	12	-	9	-	40	94
	# neck of femur (arthroplasty)	176	-	-	-	-	-	8	184
	Procedure not stated	1	-	3	-	-	-	3	7
	Total	188	187	260	11	326	6	733	1711

*These categories were formed from free-text stated by auditors

How was pre-operative anaemia investigated and managed?

- The investigation and management of anaemia takes time. Timely Hb testing is thus necessary if patients are not to be:
 - Postponed unnecessarily, at best causing them inconvenience, often distress and sometimes harm OR;
 Inappropriately transfused.
- When pre-operative anaemia is discovered during surgical work-up, it should not be seen as simply an abnormal laboratory value. Instead, it should be viewed as:

- A marker of potential undiagnosed serious disease, for example gastrointestinal cancer or renal failure.
- A modifiable risk factor for poor surgical outcome.
- Simply proceeding with planned surgery in the face of anaemia is therefore poor medicine.
- On the other hand, if anaemia is only detected close to the time of planned surgery, clinicians caring for the patient
 peri-operatively are in the invidious situation of having to choose between poor options: proceeding despite the
 above considerations, or cancelling surgery with its associated waste of resources and burden of morbidity to
 patients.
- Not detecting anaemia in a timely fashion and/or not managing it appropriately is thus a systemic failure.

Was there a haemoglobin (Hb) result at least 14 days before surgery and on/after the day of listing?

Excluding patients with fractured neck of femur, only 49% of cases (1407/2853) had an Hb result at least 14 days before surgery. Therefore it was not possible to optimise PBM in half of patients.

Nationally, the 1407 cases had Hb results a median (IQR) of 22 days (0-61 days) from listing and a median of 33 days (20-64 days) before surgery.

What were the results of Hb and other relevant investigations?

The median (IQR) Hb result taken at least 14 days before surgery was 124g/L. Further details are shown for the national dataset in the table below:

FBC results	Median	IQR	Ν
Hb result, g/L:	124	112-135	1407
MCH* result, picograms:	29.8	27-9-31.2	1302
MCV* result, femolitres	89	85-93	1377
Ferritin, μg/L:	68	27-140	205
Transferrin saturation % (TSAT)	20	12-31	48

Note that the MCV* (mean red cell volume) and MCH* (mean red cell Hb) were not given in all of the cases where the Hb result was known. Only a small proportion of cases had a ferritin measurement available and even fewer had the result of transferrin saturation

What about patients with anaemia?

Nationally, of those with an Hb result at least 14 days before surgery (1407), 46% of women and 48% of men were anaemic (defined as Hb less than 120g/L for women and less than 130g/L for men).

Nationally, of those with an Hb result at least 14 days before surgery, only 15% (205) of patients had a ferritin result available. The following table shows the full results of anaemia investigations nationally:

	National
Hb result, g/L:	
Female: median (IQR)	121 (111-130), n=896
Male: median (IQR)	131 (117-143), n=506
Females with Hb<120 g/L	46% (411/896)
Males with Hb<130 g/L	48% (244/506)

Of those with an Hb result:	
Also with a MCV result	93% (1308/1407)
Also with a Ferritin result	15% (205/1407)
Of those with an Hb result but with no Ferritin result: Also	
with a TSAT result	0.4% (5/1202)

The pre-operative anaemia standard only expects patients with anaemia to be investigated and treated for iron deficiency anaemia pre-operatively as other types of anaemia are more difficult to correct.

Did patients receive any treatment for anaemia pre-operatively?

The table below shows the treatments that were given to patients pre-operatively. This includes patients with fractured neck of femur. Only a very small proportion of patients had active treatment for anaemia, and in 279 cases, patients received a transfusion pre-operatively

		National
Known	for	3793
	Oral iron	11% (399)
	IV iron	0.8% (29)
	Erythrocytosis-stimulating agent (ESA) therapy	0.3% (12)
	B12	2% (71)
	Folic acid	4% (151)
	Red cell transfusion	7% (279)
	None	79% (3009)

Pre-operative red cell transfusion

Pre-operative transfusion should not be seen as an alternative to good practice where there is an opportunity to ensure that pre-operative anaemia is proactively managed.

Transfusion should only be considered in patients with acute blood loss or where the anaemia is not correctable and the Hb is below the defined threshold. In the audit, transfusions to patients with fractured neck of femur were excluded from the analysis of compliance with standards 1 and 3 (see PBM algorithms in Appendix 1) since this clinical scenario is often associated with blood loss.

There is no consistent evidence of benefit for transfusing at higher haemoglobin thresholds (liberal practice), and some evidence of harm.¹⁴

The use of a restrictive transfusion strategy including a single unit approach is therefore recommended. This reduces unnecessary transfusion of red cells, thus reducing cost and improving outcomes for patients.

A higher transfusion threshold of 80g/L is recommended for those with acute coronary syndrome, given uncertainty about the levels of evidence for this subgroup.¹⁴

¹⁴ Salpeter, S. R., Buckley, J. S., & Chatterjee, S. (2014). Impact of more restrictive blood transfusion strategies on clinical outcomes: a meta-analysis and systematic review. *American Journal of Medicine*, *127*, 124-13

The table below shows the median (IQR) number of days from transfusion of the first unit of red cells to surgery, nationally; the majority were given either the day before surgery or the day of surgery but before transfer to theatre. Nationally, 46% (127/278) of pre-operative transfusions were given to patients with fractured neck of femur.

	National
Median (IQR)	1 (1-2), n=278
Same day as op	19% (53)
Day before op	45% (124)
2 Days before op	13% (37)
3-5 Days before op	11% (31)
6-14 Days before OP	6% (18)
Earlier	5% (15)

The median pre-transfusion Hb result (IQR) was 82g/L (76-89) nationally and 98g/L (n=2) in your hospital.

Reasons for patients transfused at more liberal thresholds i.e. a pre-transfusion Hb of more than 70g/L (without acute coronary syndrome) or more than 80g/L (with acute coronary syndrome) are shown below for the national dataset; this was the case for the majority 81% (224/277) of pre-operative transfusions:*

		National
Rea	son known	147/224
	Acute blood loss	11% (16)
	Anticipated blood loss	11% (16)
	Anaemia	22% (32)
	Anti-platelet / Anti-coagulant	3% (5)
	Other cardiac history	16% (23)
	Infection	3% (4)
	COPD	1% (2)
	Renal disease	2% (3)
	Cancer	10% (14)
	Clinical decision - no other given for the clinical decision	6% (9)
	Hypotension	1% (1)
	Shortness Of Breath	1% (2)
	Optimisation	10% (15)
	Other	3% (5)

*These categories were formed from free-text stated by auditors

The median number of units transfused pre-operatively was 2 units.

	National
One	20% (56)
Тwo	61% (168)
Three	13% (35)
Four or more	6% (18)

The Hb result taken closest before date of surgery was available in 3685 / 3897 patients (95%). The median (IQR) Hb was 118g/L (105-131) and 58% (2136) were anaemic. Further details of national figures and for your hospital and shown here:

	National	Your hospital
Hb result, g/L:		
All patients: median (IQR)	118 (105-131), n=3685	Median: 121, n=23
Female: median (IQR)	116 (104-127), n=2371	Median: 122, n=20
Male: median (IQR)	122 (106-138), n=1291	Median: 121, n=3
Gender NK: median (IQR)	102 (95-126), n=23	
Females with Hb<120 g/L	57% (1355/2371)	N=10
Males with Hb<130 g/L	60% (781/1291)	N=10
Total anaemic (F<120, M<130)	58% (2136/3662)	
Days between pre-op Hb and surgery: median (IQR)	2 (1-13), N=3622	Median: 1, n=23

The percentage of patients found to be anaemic within the different surgical groups is shown in the table below:

TYPE OF PROCEDURE		Total anaemic
111		(F<120, M<130)
	Primary unilateral total hip replacement	52% (287/557)
	Primary bilateral total hip replacement	54% (15/28)
	Primary unilateral total knee replacement	53% (167/313)
	Primary bilateral total knee replacement	33% (9/27)
	Unilateral revision hip replacement	49% (118/243)
	Unilateral revision knee replacement	69% (43/62)
□ Iapa	Colorectal resection for any indication (open or aroscopic)	69% (192/279)
	Open arterial surgery e.g. scheduled (non- tured) aortic aneurysm repair, infrainguinal oropopliteal or distal bypass	47% (68/144)
	Primary coronary artery bypass graft	34% (39/113)
	Valve replacement +/- CABG	37% (151/406)
	Simple or complex hysterectomy	53% (168/317)
	Cystectomy	50% (17/34)
	Nephrectomy	66% (84/127)
	# neck of femur (arthroplasty)	77% (768/999)
	Procedure not stated	77% (10/13)
	Total	58% (2136/3662)

How were patients taking anticoagulants or antiplatelet agents managed pre-operatively?

Patients who do not have their oral anticoagulation or anti platelet medications withheld for at least 5 days before major elective surgery are likely to be at increased risk of bleeding during surgery (does not include aspirin).^{15,16}

To reduce the risk of bleeding, patients with fractured neck of femur on warfarin should have their anticoagulation actively managed so that their INR is 1.5 or less on the day before or the day of surgery.

The risk of bleeding versus the risk of thrombosis should be considered for each patient and an individualised management plan should be developed.^{15,16}

¹⁵Keeling, D., Baglin, T., Tait, C., Watson, H., Perry, D., Baglin, C., Kitchen, S., Makris, M. and British Committee for Standards in Haematology (2011), Guidelines on oral anticoagulation with warfarin – fourth edition. British Journal of Haematology, 154: 311–324.

¹⁶ A. D. Oprea & W. M. Popescu Perioperative management of antiplatelet therapy (2013) Br. J. Anaesth. 111 (suppl 1): i3-i17

Nationally, 710 patients had a record of receiving anticoagulant and / or antiplatelet agents (excluding aspirin) at any time in the month leading up to surgery

	National
Record	18% (710/3890)
Anticoagulant?	347
Antiplatelet agent?	349
Both	14

HOW WERE PATIENTS ON ORAL ANTICOAGULANTS MANAGED?

Patients on oral anticoagulation (e.g. warfarin, dabigatran, apixaban) should have the drug discontinued at least 5 days pre-op. The tables below show the number (%) of patients who discontinued therapy overall and by procedure (the latter shows national data only):

In the month leading up to surgery:	National	Your hospital
Patients on any oral anticoagulation	9% (361/3890)*	13% (3/23)
Stopped drug	87% (315/361) stopped	N=3
Stopped at least 5 days pre-op	48% (139/287)	n=0

One patient was on two drugs (Dabigatran & warfarin) both stopped the day before surgery

тү	PE OF PROCEDURE	On anti-coagulant	Stopped anticoagulant	Stopped at least 5 days before Op
	Primary unilateral total hip replacement	46	43	25/39
	Primary bilateral total hip replacement	3	3	0/2
	Primary unilateral total knee replacement	25	22	13/19
	Primary bilateral total knee replacement	-	-	-
	Unilateral revision hip replacement	31	29	13/27
	Unilateral revision knee replacement	7	7	5/7
	Colorectal resection for any indication	22	21	13/18
	Open arterial surgery	17	16	11/15

Primary coronary artery bypass graft		9	9	5/7
Valve replacement +/- CABG		79	65	42/56
Simple or complex hysterectomy		8	7	4/6
Cystectomy		2	2	0/1
Nephrectomy		9	7	5/7
# neck of femur (arthroplasty)		103	84	3/83
Procedure not stated		-	-	-
	Total	361	315	139/287

Nationally, 15 patients were on apixaban, 14 patients were on dabigatran, 38 patients were on rivaroxaban and 293 patients were on warfarin.

For those patients on warfarin, the median (IQR) INR result was 1.3 (1.1-1.5) (n=305) The more detailed breakdown for national data is shown in the table here:

	National
Patient on Warfarin pre-operatively	8.3% (318/3813)
INR result taken closest before surgery for	
those on Warfarin pre-operatively:	
□ ≤1.0	49
□ 1.1-1.4	164
□ 1.5-1.9	50
□ 2.0-2.4	17
□ 2.5-2.9	6
□ 3.0-3.4	7
□ 3.5-4.4	8
□ 4.5-5.9	2
□ 6.0-7.9	-
□ ≥8.0	2
Median (IQR) INR result	1.3 (1.1-1.5), n=305
Days between INR and surgery:	
Same day as op	106
Day before op	131
□ Earlier	63
Median (IQR) days before op	1 (0-1), n=300

HOW WERE PATIENTS ON ANTIPLATELET AGENTS MANAGED?

Patients on **antiplatelet therapy** (e.g. clopidogrel, prasugrel, ticagrelor) should have the drug discontinued at least 5 days pre-operatively unless there is a good reason to continue it. Aspirin does not count towards this standard. The tables below show the number (%) of patients who discontinued therapy overall and by procedure (the latter shows national data only).

	National	Your hospital
Patients on any antiplatelet therapy*	9.3% (363/3890)	0% (0/23)

Stopped therapy	77% (279/363)	N=-
Stopped at least 5 days pre-op	57% (149/261)	N=23

* This count excludes aspirin. Note also that there were five of these patients who were on clopidogrel and ticagrelor. Two stopped clopidogrel within 5 days of surgery while three were not stopped. All five stopped ticagrelor, four at least 5 days before surgery. However only two stopped both drugs, which is what is counted here and none had both drugs stopped at least 5 days before surgery.

TYF	PE OF PROCEDURE	On anti-platelet	Stopped antiplatelet	Stopped at least 5 days before Op
	Primary unilateral total hip replacement	33	31	22/28
	Primary bilateral total hip replacement	2	1	1/1
	Primary unilateral total knee replacement	13	12	8/9
	Primary bilateral total knee replacement	-	-	-
	Unilateral revision hip replacement	15	14	7/13
	Unilateral revision knee replacement	4	4	2/3
	Colorectal resection for any indication	13	12	11/12
	Open arterial surgery	42	23	17/23
	Primary coronary artery bypass graft	42	34	25/32
	Valve replacement +/- CABG	66	56	36/54
	Simple or complex hysterectomy	6	4	3/3
	Cystectomy	-	-	-
	Nephrectomy	11	11	8/9
	# neck of femur (arthroplasty)	114	75	7/72
	Procedure not stated	2	2	2/2
		Total 363	281	149/261

Nationally, 337 patients were on clopidogrel, 2 patients were on prasugrel, 29 patients were on ticagrelor. 654 patients were on aspirin.

Of the 337 patients on clopidogrel, 82 patients continued on this drug: 10 because of acute coronary syndrome, 34 the reason was not recorded and 38 for other reasons including need for emergency surgery and patients with severe vascular disease.

Patient Blood Management whilst in theatre and recovery

PBM in the intra-operative period includes the use of antifibrinolytics such as tranexamic acid; there is accumulating evidence that tranexamic acid is safe and effective when used to reduce blood loss and minimise transfusion requirements in elective surgery; it is likely to be highly cost-effective.¹⁵

Other measures that should be attempted where appropriate include the use of cell salvage and haemostatic sealants.

Near patient testing of haemostasis is recommended for use particularly in cardiac surgery where studies have shown improved patient outcomes with the targeted management of coagulopathy¹⁸

When was tranexamic acid used?

Tranexamic acid was used in 1252/3805 cases (33%) nationally and in your hospital in 1/19 cases (5%). The majority of treatment was given intravenously and intra-operatively as shown in the table below:

	National	Your hospital
Tranexamic acid used	33% (1252/3805)	5% (1/19)
	25	
Oral, before surgery started	25	0
Oral, during surgery	1	0
Oral, after surgery	7	0
IV, before surgery started	368	0
IV, during surgery	912	1
IV, after surgery	66	0
Intra-articular, during surgery	1	0
Intra-articular, after surgery	-	-
Not known when TXA given known	18	0

Tranexamic acid was used most commonly in patients undergoing cardiac surgery, followed by those undergoing elective orthopaedic surgery. Further detail is shown here:

ТҮРІ	E OF PROCEDURE	Tranexamic acid used
	Primary unilateral total hip replacement	47% (279/588)
	Primary bilateral total hip replacement	53% (16/30)
	Primary unilateral total knee replacement	38% (126/333)
	Primary bilateral total knee replacement	52% (14/27)
	Unilateral revision hip replacement	64% (162/255)
	Unilateral revision knee replacement	50% (33/66)

¹⁵ Ralley F. Tranexamic acid: When is enough (data) enough? Canadian Journal of Anesthesia 2015. doi:10.1007/s12630-015-0461-5. ¹⁸ Detecting, managing and monitoring haemostasis: viscoelastometric point-of-care testing (ROTEM, TEG and Sonoclot systems) (2014) <u>http://www.nice.org.uk/Guidance/DG13</u> accessed 20th Sept 2015

²⁰¹⁵ Audit of Patient Blood Management in Adults undergoing elective, scheduled surgery Supplementary Information Report Page 25

Colorectal resection for any indication		6% (16/287)
Open arterial surgery e.g.: scheduled		7% (10/152)
Primary coronary artery bypass graft		88% (101/115)
Valve replacement +/- CABG		73% (304/419)
Simple or complex hysterectomy		15% (51/332)
Cystectomy		12% (4/34)
Nephrectomy		10% (13/130)
# neck of femur (arthroplasty)		12% (120/1026)
Procedure not stated		27% (3/11)
	Total	33% (1252/3805)

Aprotinin was used in 32 cases (0.8%) nationally*

*Valve replacement +/- CABG (n=20), Primary coronary artery bypass graft (n=7), Primary unilateral total hip replacement (n=2), Open arterial surgery (n=2), Simple or complex hysterectomy (n=1)

Were topical haemostatic agents/sealants used?

Haemostatic agents were used in 200 cases (5.3%) nationally, although of these 59 should not have been recorded in this category. See the table here for further detail and for your hospital results:

		National	Your hospital
Hae	mostatic agents or sealants used	5.3% (200/3802)	0% (0/18)
Wh	at was used:*		
	Fibrin 7 thrombin sealants	72	
	Surgical adhesives & absorbable	61	
	haemostatic dressings		
	Both the above	3	
	Others - i.e. not sealants and should	59	
	not really be in this category		
	Not stated	5	

*These categories were formed from free-text stated by auditors

The sealants were mainly used in cardiac surgery and nephrectomy. Further details are shown here for the national dataset:

TYF	PE OF PROCEDURE	Haemostatic agents or sealants used
	Primary unilateral total hip replacement	1% (6/587)
	Primary bilateral total hip replacement	0% (0/30)
	Primary unilateral total knee replacement	2% (6/335)
	Primary bilateral total knee replacement	11% (3/27)
	Unilateral revision hip replacement	2% (6/256)

Unilateral revision knee replacement		0% (0/66)
Colorectal resection for any indication		4% (12/288)
Open arterial surgery e.g.: scheduled		7% (11/152)
Primary coronary artery bypass graft		24% (28/115)
Valve replacement +/- CABG		17% (69/418)
Simple or complex hysterectomy		10% (33/332)
Cystectomy		3% (1/32)
Nephrectomy		16% (21/129)
# neck of femur (arthroplasty)		0.4% (4/1024)
Procedure not stated		0% (0/11)
	Total	5% (200/3802)

Was intra-operative cell salvage utilised?

Collection for intra-operative cell salvage (IOCS) was commenced in 521 cases (14%). Of these, in 459 cases the red cells were reinfused. In 60 cases, the red cells were collected but not reinfused due to insufficient volume. The median (IQR) volume returned was 496 ml (303-714). Details for the national position and your hospital are shown below:

	National	Your hospital
Commenced	14% (521/3826)	0% (0/20)
Outcome of using IOCS:		
Collected but not reinfused due to insufficient volume	60	-
Collected and reinfused*	459	-
Not known	2	
		-
*Volume reinfused (ml): median (IQR)	496 (303-714), n=429	

The reasons that IOCS was not utilised are recorded in the table below (national data)

Why was cell salvage not commenced N=3305

	National
IOCS was not available on the day of surgery	7% (229)
Not worthwhile in this procedure as anticipated blood loss generally too low	40% (1320)
Not considered in this procedure because of contaminated field	2% (76)
Not considered in this procedure because of sepsis	1% (36)
Not considered in this procedure because of malignancy	7% (237)
Other reasons*	37% (1228)
Cell salvage not available	374
Miscellaneous clinical reasons	228

Reason not recorded	626
Not known	5% (179)

*These categories were formed from free-text stated by auditors

ТҮІ	PE OF PROCEDURE	NATIONAL intra-operative cell salvage (IOCS) commenced
	Primary unilateral total hip replacement	4% (25/591)
	Primary bilateral total hip replacement	13% (4/30)
	Primary unilateral total knee replacement	8% (26/335)
	Primary bilateral total knee replacement	7% (2/27)
	Unilateral revision hip replacement	24% (62/256)
	Unilateral revision knee replacement	5% (3/66)
	Colorectal resection for any indication	0% (0/294)
	Open arterial surgery e.g.: scheduled	42% (64/154)
	Primary coronary artery bypass graft	63% (72/115)
	Valve replacement +/- CABG	55% (229/420)
	Simple or complex hysterectomy	4% (13/337)
	Cystectomy	6% (2/35)
	Nephrectomy	8% (10/130)
	# neck of femur (arthroplasty)	1% (6/1025)
	Procedure not stated	27% (3/11)
	Tota	l 14% (521/3826)

The types of procedure where IOCS was commenced is shown below

Was near patient testing of haemostasis utilised?

Near patient testing of haemostasis was used in 579 cases (15%) of cases nationally. Activated clotting time was the most commonly performed test. The table here shows more detail for national and your hospital:

			•
		National	Your site
Near pa	atient testing of haemostasis undertaken	15% (579/3778)	-% (-/0)
Near n	atient testing options undertaken:	Known for 572	0
incui pi	dient testing options under taken.		•
	TEG	35% (199)	-
	RoTEM	6% (36)	-
_		22((12)	
	Platelet function testing	2% (12)	-
	Activated Clotting Time	69% (396)	-
ļ.			

□ Other*

*other : consisted mainly of free text entries which largely consisted of blood gas analysis rather than near patient testing of haemostasis

The types of procedure where near patient testing of haemostasis was utilised is shown in the table for national data. These tests are most commonly used in cardiac surgery.

түр	E OF PROCEDURE		NATIONAL Near patient testing of haemostasis undertaken
	Primary unilateral total hip replacement		2% (11/586)
	Primary bilateral total hip replacement		3% (1/30)
	Primary unilateral total knee replacement		1% (3/331)
	Primary bilateral total knee replacement		4% (1/27)
	Unilateral revision hip replacement		4% (10/254)
	Unilateral revision knee replacement		0% (0/64)
	Colorectal resection for any indication		3% (8/288)
	Open arterial surgery		19% (28/151)
	Primary coronary artery bypass graft		94% (108/115)
	Valve replacement +/- CABG		88% (354/402)
	Simple or complex hysterectomy		6% (21/334)
	Cystectomy		9% (3/33)
	Nephrectomy		9% (11/129)
	# neck of femur (arthroplasty)		2% (18/1023)
	Procedure not stated		18% (2/11)
		Total	15% (579/3778)

Intra-operative allogeneic red cell transfusion

Intra-operative transfusion is defined as any transfusion occurring during surgery or prior to departure from recovery using allogeneic red cells issued by the transfusion laboratory. This occurred in 25% (982/3851) of cases nationally and 4% (1/23) in your hospital.

The Pre-transfusion Hb

The pre-transfusion Hb was checked within 1 hour before transfusing the first intra-operative unit in 631 cases (70%) nationally. The table here shows a breakdown of how the Hb was checked, both nationally and for your hospital:

	National	Your hospital
Pre-transfusion Hb checked	70% (631/898)	0% (0/1)
How was it checked:		
Laboratory Hb from FBC sample	42	-

Hb from blood gas analyser	405	-	
Hb from 'Masimo'	1	-	
Hb from Haemocue	165	-	
Other*	10		
Not known	8	-	
	Hb from 'Masimo' Hb from Haemocue Other*	Hb from 'Masimo'1Hb from 'Masimo'1Hb from Haemocue165Other*10	Hb from 'Masimo'1Hb from 'Masimo'1Hb from Haemocue165Other*10

Other* Method of check not documented

There were 604 cases nationally where the pre-transfusion Hb result was recorded. The median result from the national dataset and your hospital are shown here:

	National	Your hospital
Median Hb (IQR) g/L	83 (75-95), n=604	-%, n=0

Further details about the characteristics of the intra-operative transfusion episodes are shown here using the national dataset:

ТҮР	E OF PROCEDURE		Any intra-operative transfusion with allogeneic red cells issued by the transfusion laboratory	Pre-transfusion Hb checked within 1 hour before transfusing the first unit	(if checked <1 hr) MEDIAN First intra-operative pre-transfusion Hb g/L
	Primary unilateral total hip replacement		13% (78/601)	59% (42/71)	86, n=40
	Primary bilateral total hip replacement		23% (7/30)	71% (5/7)	84, n=5
	Primary unilateral total knee replacement		4% (13/337)	75% (9/12)	94, n=9
	Primary bilateral total knee replacement		4% (1/27)	0% (0/1)	-
	Unilateral revision hip replacement		34% (86/254)	69% (55/80)	90, n=53
	Unilateral revision knee replacement		15% (10/67)	50% (4/8)	82, n=4
	Colorectal resection for any indication		39% (116/296)	64% (65/102)	83, n=63
	Open arterial surgery e.g.: scheduled (41% (62/152)	72% (43/60)	84, n=43
	Primary coronary artery bypass graft		39% (45/115)	93% (38/41)	76, n=36
	Valve replacement +/- CABG		44% (184/419)	89% (150/168)	79, n=146
	Simple or complex hysterectomy		34% (114/339)	59% (59/100)	83, n=56
	Cystectomy		36% (13/36)	80% (8/10)	84, n=8
	Nephrectomy		53% (69/130)	70% (46/66)	83, n=43
	# neck of femur (arthroplasty)		17% (180/1034)	62% (104/168)	82, n=95
	Procedure not stated		29% (4/14)	75% (3/4)	77, n=3
		Total	25% (982/3851)	70% (631/898)	83, n=604

THE REASON FOR TRANSFUSION

Active bleeding¹⁶ was given as the reason for intra-operative transfusion in 65% of cases (615/944). In 406 cases the estimated blood loss was given and the median (IQR) was 1184 (644-1940) ml. Further details including reasons transfusion was given in the absence of active bleeding are shown here both for the national dataset and your hospital:

THE NUMBER OF RED CELL UNITS TRANSFUSED AND THE POST-TRANSFUSION HB

Nationally, 82% of cases received 2 units or fewer intra-operatively. Further details for the national dataset and your hospital are shown here:

	National	Your hospital
Zero	0.5% (4)	
One	32% (288)	0
Two	50% (443)	1
Three	7% (63)	0
Four	6% (57)	0
Five to Nine	3% (30)	0
Ten or more	0.6% (5)	0

The Hb was checked on arrival in recovery in 35% (1306/3775) cases. Details of the median (IQR) Hb result for the national dataset and your hospital are shown here:

	National	Your hospital
Hb taken on arrival in recovery	35% (1306/3775)	13% (3/23)
Median (IQR)	97 (87-109), n=1277	Median: 89, n = 3

¹⁶ Active intra operative bleeding was defined as significant blood loss with haemodynamic instability in the audit protocol

		National	Your hospital
Pat	ient had active bleeding	65% (615/944)	0% (0/1)
Esti	mated blood loss (EBL) in ml:		
Me	dian (IQR)	1184 (644-1940), n=406	
	If patient did not have active blee	eding why were they transfu	sed:*
	Low BP or other hemodynamic reason	35	
	Hb drop	167	
	Blood loss - any volume recorded	16	
	Not known	111	

*These categories were formed from free-text stated by auditors

Patient Blood Management in the post-operative period

With the introduction of enhanced recovery pathways, the use of drains and therefore post-operative cell salvage is becoming less commonly used. In this audit, this procedure was considered optional¹⁹

There is very little evidence to support the use of post-operative iron; further research is required²⁰

¹⁹.Varandhan, KK, Lobo DN, Ljungqvist O, (2010) Enhanced Recovery After Surgery: The Future of Improving Surgical Care. Crit Care Clin. 26 :527-47 ²⁰ Hogan, M; Klein, AA; Richards, T; (2015) The impact of anaemia and intravenous iron replacement therapy on outcomes in cardiac surgery. Eur J Cardiothorac Surg, 47 218-226.

Post-operative cell salvage

This was a relatively rare procedure occurring in 70 cases (1.9%) nationally; the technique usually used was reinfusion of shed blood. The table below shows more detail:

Post-operative cell salvage

	National	Your hospital
Post-operative cell salvage used*	1.9% (70/3782)	0% (0/20)
Which post-op cell salvage technique(s)		
was/were used:		
Reinfused shed blood	51/67	
Washed red cells	15/68	
Other	1/68	
Total volume in ml of post-operative		
salvaged blood infused: median (IQR) 🛛		
median (IQR)	300 (200-500), n=46	

*Primary unilateral total knee replacement (N=34), Valve replacement +/- CABG (N=12), Primary unilateral total hip replacement (N=8), Unilateral revision hip replacement (N=7), other procedures (N=9).

Post-operative Hb and use of post-operative iron

The first Hb result taken on day 1 (the next calendar day after surgery) was available in 3312 cases and the median (IQR) result was 91g/L (83-102) nationally and was available in 17 cases at your hospital with a median of 89g/L.

Post-operative iron was given in 17% of cases (630/3782) nationally. Further details for the national dataset and for your hospital are given here:

	National	Your hospital
Patient given post-operative iron	17% (630/3782)	5% (1/20)
Given orally	609/619	1/1
Given as IV	10/619	-/1

The type of procedure where post-operative iron was given is shown here for the national dataset:

TYPE O	F PROCEDURE	NATIONAL Post-operative iron	
D PI	rimary unilateral total hip replacement	17% (100/579)	

Primary bilateral total hip replacement		13% (4/30)
Primary unilateral total knee replacement		15% (48/330)
Primary bilateral total knee replacement		22% (6/27)
Unilateral revision hip replacement		11% (28/252)
Unilateral revision knee replacement		21% (14/66)
Colorectal resection for any indication		12% (35/289)
Open arterial surgery e.g.: scheduled		11% (16/151)
Primary coronary artery bypass graft		11% (12/112)
Valve replacement +/- CABG		11% (46/417)
Simple or complex hysterectomy		39% (131/338)
Cystectomy		3% (1/35)
Nephrectomy		13% (17/129)
# neck of femur (arthroplasty)		17% (170/1016)
Procedure not stated		18% (2/11)
	Total	17% (630/3782)

Post-operative red cell transfusion

Nationally, 74% of patients (2878/3874) received at least one post-operative transfusion up to 7 days following surgery. 80% of these (2307) had a single transfusion episode. Further details from the national dataset and for your hospital are shown here:

T		and the second s	- /: - D-	
I ranstusion on an	y of the first seven	post-operative day	's (I.e. Da	$y \perp to aay 7$

	National	Your hospital
Transfusion	74% (2878/3874)	78% (18/23)
How many episodes:* One	80% (2307)	
Тwo	13% (360)	
Three	2.2% (62)	
Four	0.3% (10)	
Five	<0.1% (2)	
Not known	4.8% (137)	

*A transfusion episode = any red cells transfused within a 24 hour period

Post-operative transfusion rates for the different procedures are shown here for national data:

TYPE OF PROCEDURE	Transfusion on any of the first seven post-operative days
-------------------	---

Primary unilateral total hip replacement		86% (520/607)
Primary bilateral total hip replacement		73% (22/30)
Primary unilateral total knee replacement		87% (293/336)
Primary bilateral total knee replacement		93% (25/27)
Unilateral revision hip replacement		67% (172/257)
Unilateral revision knee replacement		88% (59/67)
Colorectal resection for any indication		54% (161/297)
Open arterial surgery		59% (90/153)
Primary coronary artery bypass graft		80% (92/115)
Valve replacement +/- CABG		72% (302/421)
Simple or complex hysterectomy		62% (212/342)
Cystectomy		70% (26/37)
Nephrectomy		49% (64/130)
# neck of femur (arthroplasty)		80% (827/1040)
Procedure not stated		87% (13/15)
	Total	74% (2878/3874)

Characteristics of the first post-operative transfusion episode are shown here for the national dataset:

		NATIONAL
		N=2868
Da	ys from surgery: median (IQR)	2 (1-3) N=2805
	ho made the decision to transfuse: (These categories ere formed by the auditors)	
	Consultant- Anaesthetics & critical care	226
	Consultant - Other specialty	332
	Consultant - Specialty not known	259
	Senior trainee - Anaesthetics & critical care	61
	Senior trainee - Other specialty	242
	Senior trainee - Specialty not known	142
	Junior trainee - Anaesthetics & critical care	14
	Junior trainee - Other specialty	225
	Junior trainee - Specialty not known	469
	Grade NK - Anaesthetics & critical care	149
	Grade NK - Other specialty	205
	Grade NK - Specialty not known	536
	Nurse	8
Pr	e-transfusion Hb*, g/L: median (IQR)	79 (74-85) n=2717
Ur	its of red cells given:	N=2842
	□ One	31% (892)

Image: Three 5% (149) Image: Four or more 3% (72)	
Hb recorded after each unit of red cells 29% (823/282	L8)
Patient had acute coronary ischaemia 6.0% (167/27	94)
Reason for transfusion:	
Active256	
bleeding***	
 An Hb <70 g/L without acute coronary syndrome 304 	
□ An Hb <80 g/L with acute coronary syndrome 134	
D Other**** 2115	
Low BP or other hemodynamic reason 394	
□ Hb drop 1242	
Blood loss - any volume recorded107	
Not known 372	
D Not known 59	

* within 12 hours of transfusion

*** Active post-operative bleeding defined as bleeding causing systolic Hb <90mmHg, and or heart rate >110bpm, and or return to theatre because of bleeding and or activation of major haemorrhage pathway.

****These categories were formed from free-text stated by auditors: FIRST transfusion only

What was the patient outcome post-operatively?

Information about whether there were complications of surgery was recorded in 3755 cases. The table here shows the breakdown of the type of complication for the national dataset and your hospital: Complications of surgery N=3755

0	,	National	Your hospital
	No complications noted	78% (2938)	76% (16/21)
	Return to theatre	5.2% (195)	1
	VTE	0.5% (19)	0
	Wound infection	2.5% (92)	0
	Positive blood culture	0.5% (18)	0
Any of	the above 4 complications	8.0% (301)	(1/21)
	Others	16% (603)	5

Complications by type of procedure are shown here for the national dataset:

TY	PE OF PROCEDURE	Return to theatre	VTE	Wound infection	Positive Blood culture	Any of these 4 complications	Total cases
	Primary unilateral total hip replacement	7	4	11	1	3.4% (20)	581
	Primary bilateral total hip replacement	-	-	-	-	-	29

Primary unilateral total knee replacement	: 1	5	6	-	3.7% (12)	328
Primary bilateral total knee replacement	-	-	-	-	-	26
Unilateral revision hip replacement	6	1	11	1	6.5% (16)	245
Unilateral revision knee replacement	2	-	4	-	9.1% (6)	66
Colorectal resection	35	-	15	4	18% (53)	289
Open arterial surgery	20	-	8	2	18% (28)	152
Primary coronary artery bypass graft	13	-	4	2	16% (18)	112
Valve replacement +/- CABG	43	-	5	2	12% (48)	411
Simple or complex hysterectomy	42	-	6	-	14% (48)	332
Cystectomy	5	-	1	-	14% (5)	35
Nephrectomy	7	-	3	1	8.6% (11)	128
# neck of femur (arthroplasty)	14	9	18	5	3.6% (36)	1012
Procedure not stated	-	-	-	-	-	9
Total	195	19	92	18	8.0% (301)	3755

Transfusion reactions were reported rarely and details provided were sketchy.

	National
ANY adverse reaction	0.9% (23/2683)
Type of blood that caused the reaction: Autologous Allogeneic	- 23
N=30 reactions from 23 cases Days from surgery: median (IQR)	2 (2-4), range 0-7, n=29

The commonest type of reaction was a mild febrile type, not considered severe enough for reporting to SHOT. There was one possible case of transfusion associated circulatory overload.

138(3.6%) patients died during the surgical admission. Further details are given here for the national dataset and your hospital:

	National	Your hospital
Patient died	3.6% (138/3874)	4% (1/23)
Days from surgery		
To date of death: median (IQR)	12 (6-24), n=138	Median: 4,n=1
To discharge: median (IQR)	8 (6-14), n=3670	Median: 13, n=22

DISCHARGE Hb

The median Hb (IQR) at discharge was 102g/L (94-109). Further details are given here for both the national dataset and your hospital.

Hb on or nearest to discharge/death (g/L)

	National	Your hospital
All patients: median (IQR)	102 (94-109), n=3764	Median: 109, n=23
Days from surgery to Hb: median (IQR)	7 (4-12), n=3703	

Limitations of the audit

There were a number of limitations to this audit. Only transfused patients were analysed; excluding who were not transfused may mean that we have missed the opportunity to identify those cases where excellent PBM practice was applied.

Patients with fractured neck of femur were included even though they were not elective cases in order to increase the number of cases in the audit. However, these patients accounted for 27% of the dataset and were significantly older and more likely to be female. This group was excluded from the analysis of pre-operative anaemia optimisation.

Restrictive transfusion thresholds were selected in line with the accumulating evidence. However there remains controversy about the transfusion threshold for patients undergoing cardiac surgery and those with coronary disease in general where a higher threshold may be appropriate, and in the audit a strict definition of acute coronary syndrome was the only allowance for a higher pre-transfusion Hb threshold of 80g/L

The audit can only assess what is recorded in clinical records and may not have been able to account for all aspects of clinical decision-making. However, good clinical record keeping is increasingly recognised as a core feature of sound and safe clinical practice.

Discussion

There has been an excellent participation rate by UK and Republic of Ireland hospitals and the number of cases represents the largest audit of PBM practice in surgical patients in the UK to date.

There is evidence of some excellent practice; for example, 85% of patients receiving a post-operative transfusion had at least one PBM measure applied.

There is room for improvement however against most of the audit standards, in particular the proactive management of pre-operative anaemia, the use of tranexamic acid and cell salvage during surgery and the adoption of a restrictive approach to transfusion in stable non-bleeding patients through the use of a lower Hb threshold than is current practice and a single unit policy.

The key and full findings reports clearly compare the results of individual hospitals against national data for each of the standards and a set of recommendations have been developed to support implementation of service improvement. This supplementary report provides further detailed information on the audit data which will also help hospitals target their activities appropriately.

The implementation of PBM will be further strengthened by the publication of the NICE Clinical Guideline on Transfusion and the Choosing Wisely campaign of the Academy of Medical Royal Colleges which will have 5 key messages about PBM.

Abbreviations


BP	Blood pressure
CABG	Coronary artery bypass graft
Hb	Haemoglobin
INR	International normalised ratio
IOCS	Intra operative cell salvage
IQR	Inter quartile range
IV	Intra venous
MCH	Mean cell haemoglobin
MCV	Mean cell volume
NHSBT	NHS Blood and Transplant
OPCS4	OPCS Classification of Interventions and Procedures
PBM	Patient blood management
RoTEM	Rotational thromboelastometry
SHOT	Serious hazards of transfusion
TEG	Thromboelastography

VTE Venous thromboembolism


Appendix 1

PBM algorithms


Algorithm for PBM standard 1 : Pre operative anaemia management




Algorithm for PBM standard 2 : Pre operative transfusion allowed




Algorithm for PBM standard 3 : Pre operative transfusion allowed only if preoperative anaemia optimisation has been attempted where



Algorithm for PBM standard 4 : Pre operative transfusion – single unit transfusion policy



Algorithm for PBM standard 5 : Pre operative anticoagulant and antiplatelet management




Algorithm for PBM standard 6 : Patients having Intra operative transfusion in whom at least one PBM measure has been attempted

(where	e appropria	Q4 transi	All Patients	geneic	Not 46	2869
		What	type of surger	y? Q6 K	nown for 978	>
Elective orthopaedic a-f	#NOF n	Colorectal g	Arterial h	Cardiac i,j	Urology I,m	Gynaecology k
		Were any P	BM measures a	ttempted?		
Meets pre op	anaemia stand	lard? Standard	1			
Yes / No / NK 93 / 102 / 0	N/A	Yes / No / NK 30 / 86 / 0	Yes / No / NK 22 / 40 / 0	Yes / No / NK 106 / 122 / 1	Yes / No / NK 28 / 54 / 0	Yes / No / NK 37 / 77 / 0
Meets pre op	anticoagulant	/ antiplatelet st	tandard? Stand	lard 5		
Yes / No / Ex / NK 13 /14 /166 / 2	Yes / No / Ex / NK 13 / 5 / 158 / 4	Yes / No / Ex / NK 5 /3 /107 /1	Yes / No / Ex / NK 16 / 9 / 37 / 0	Yes / No / Ex / NK 54 / 25 / 144 / 6	Yes / No / Ex / NK 4 / 3 / 74 / 1	Yes / No / Ex / NK 2 / 1 / 111 / 0
Meets TXA / A	Aprotonin stand	dard? Q35=pre,	/intra TXA or Q	36=yes	<u> </u>	<u> </u>
	N/A	Yes / No / NK 12 / 98 / 6	Yes / No / NK 8 / 53 / 1	Yes / No / NK 187 / 39 / 3	Yes / No / NK 11 / 68 / 3	Yes / No / NK 25 / 83 / 6
Yes / No / NK 124 / 64 / 7		,, .				
124 / 64 / 7	vage standard) no plus Q42=r			

If yes to any (where applicable) standard is met

If no to all (where applicable) standard is not met

Algorithm for PBM standard 7 : Patients having Intra operative transfusion in whom all PBM measures has been attempted (where appropriate)




Yes /No/ NK 49/42/0	Yes /No/ NK 44 / 60 / 0	N/A	Yes / No / NK 30 / 86 / 0	Yes / No / NK 22 / 40 / 0	Yes / No / NK 106 / 122 / 1	Yes / No / NK 28 / 54 / 0	Yes / No / NK 37 / 77 / 0
Meets pre o	op anticoagula	ant / antiplate	elet standard	? Standard 5			<u>.</u>
Yes/No/Ex/NK 6 / 2 / 83 / 0	Yes/No/Ex/NK 7 / 12 / 83 / 2	Yes/No/Ex/NK 13 / 5 / 158 / 4	Yes/No/Ex/NK 5 /3 /107 /1	Yes/No/Ex/NK 16 / 9 / 37 / 0	Yes/No/Ex/NK 54 /25 / 144/6	Yes/No/Ex/NK 4 / 3 / 74 / 1	Yes/No/Ex/NH 2 / 1 / 111 / 0

Meets cell	salvage stand	ard Q40 yes c	or Q40 no plu:	s Q42=reasor	is b,c,d,e		
N/A	Yes /No / NK 47 / 54 / 3	N/A	N/A	Yes / No / NK 45 / 14 / 3	Yes / No / NK 166 / 57 / 6	N/A	N/A


If yes to all (where applicable) standard is met

If no to any (where applicable) standard is not met


Algorithm for PBM standard 8 : Post operative transfusion allowed (whether or not PBM measures attempted) – FIRST transfusion episode



Algorithm for PBM standard 9 : Post operative transfusion following the single unit policy (FIRST episode)?



Algorithm for PBM standard 10 : Patients having post operative transfusion in whom at least one PBM measure has been attempted (where appropriate) (FIRST EPISODE)



If yes to any (where applicable) standard is met

If no to all (where applicable) standard is not met Algorithm for PBM standard 11 : Patients having post operative transfusion in whom all PBM measures have been attempted (where appropriate) (FIRST EPISODE)

			All Pa	(day 1 to day		Excluded	
		\ [What type of s	surgery?	Known fo	r 2865	
Primary ortho a,c	Revision / bilateral ortho b,d,e,f	#NOF (Colorecta I g	Arterial h	Cardiac i,j	Urology I,m	Gynaecology k
		Were	any PBM mea	asures attemp	oted?		
Meets pre o	op anaemia si	andard? Star	ndard 1				
Yes /No / NK 481 / 332 / 0	Yes /No / NK 140 / 138 / 0	N/A	Yes /No / NK 43/ 118 / 0	Yes /No / NK 30 / 60 / 0	Yes /No / NK 151 / 241 / 2	Yes /No / NK 39 / 51 / 0	Yes /No / NK 83 / 129 / 0
Meets pre o	op anticoagul	ant / antiplat	elet standard	? Standard 5	1		•
Yes/No/Ex/NK 56/28/716/13	Yes/No/Ex/NK 20/22/231/5	Yes/No/Ex/NK 32 /31/752/12	Yes/No/Ex/NK 11 / 4 / 143 / 3	Yes/No/Ex/NK 23 / 9 / 57 / 1	Yes/No/Ex/NK 81 /49 /251/13	Yes/No/Ex/NK 10 / 3 / 76 / 1	Yes/No/Ex/NF 5 / 5 / 200 / 2
Meets TXA	/ Aprotonin s	tandard? Q3	5 =yes or Q36	= yes	<u> </u>		
Yes /No / NK 325 / 459 / 29	Yes /No / NK 150 / 124 / 4	N/A	Yes /No / NK 3 / 148 / 10	Yes /No / NK 7 / 80 / 3	Yes /No / NK 312 / 80 / 2	Yes /No / NK 8 / 80 / 2	Yes /No / NK 29 / 175 / 8
	salvage stand	ard Q40 yes c	or Q40 no plu	s Q42=reasor	ns b,c,d,e		
Meets cell s			1	Yes /No / NK	Yes /No / NK	N/A	1
Meets cell s	Yes /No / NK 142 / 119 / 17	N/A	N/A	56 / 27 / 7	289/94/11	N/A	N/A
N/A						N/A	N/A

If yes to all (where applicable) standard is met

If no to any (where applicable) standard is not met

Audit tool



National Comparative Audit of Blood Transfusion



¹⁷ Audit of Patient Blood Management in Adults undergoing Scheduled Surgery

PATIENT AUDIT BOOKLET

Audited patient number

¹⁷ Audit of Patient Blood Management in Adults undergoing elective, scheduled surgery

Auditor (s) job title	
A. Patient demographics	
Q1. What was the patient's year of birth?	
Q2. Was the patient 🗌 Male?	Female?
B. Patient Blood Management in the period fro	om listing for surgery to going to theatre
Q3. On what date was the patient listed for surg	gery? ddmmyy
Q4. For what date was the surgery scheduled?	
Q5. What was the actual date of surgery?	
Q6. What was the type of procedure? (Tick one	option)
Primary unilateral total hip replacement	
Primary bilateral total hip replacement	
Primary unilateral total knee replacement	
Primary bilateral total knee replacement	
Unilateral revision hip replacement	
Unilateral revision knee replacement	
Colorectal resection for any indication (open	or laparoscopic)

Open arterial surgery e.g.: scheduled	(non-ruptured)	aortic	aneurysm	repair,
infrainguinal femoropopliteal or distal bypass				
Primary coronary artery bypass graft				
Valve replacement +/- CABG				
Simple or complex hysterectomy				
Cystectomy				
Nephrectomy				
🗌 # neck of femur (arthroplasty)				
Q7. Did the patient have a pre-operative assessr	nent?			

Yes Now go to Q8	NO Now go to Q11	

Q8. On what date did the patient have their first pre-operative assessment?

Q9. Who is responsible for reviewing the results of investigations taken at the pre-operative assessment?

Not known	
Doctor – discipline and rank	

Q10. If the pre-operative assessment took place less than 4 weeks before surgery what was the reason?

Q11. Were FBC results available in the time between listing for surgery and up to 14 days before surgery?

Yes Now go to Q12 No Now go to Q20

Q12. On what date during the time between listing for surgery and up to 14 days before surgery were the FBC results first available?

Q13. What was the Hb result?	g/L	
Q14. What was the MCH result?	picograms	OR 🗌 Not available

Q15. What was the MCV result? <i>femolitres</i> OR Not available
Q16. Was ferritin checked? Yes <i>Now go to Q17</i> No <i>Now go to Q18</i> Q17. If yes, what was the ferritin
result?
(State unit of measurement as well as value, and include reference range) THEN GO TO Q18
Value Unit of measurement Reference range
Q18. Was a transferrin satu
done?
Yes Now go to Q19 No Now go to Q20
Q19. What was the transferrin saturation? %
Q20. Was the patient on any of the following treatments before they had their operation? None Oral iron IV iron Erythrocytosis-stimulating agent (ESA) therapy B12 Folic acid Red cell transfusion - Ticking this means the patient had a red cell transfusion before they went to theatre. Now go to Q21 to record details of that transfusion episode. Details of allogeneic red cell transfusion in theatre are recorded at Q45.
NB: If you did not tick Red cell transfusion DO NOT complete this section. Go to Q28. Q21.
What was the date and time of transfusion of the first unit? Date ddmmyy Time hh:mm
Q22. Who made the decision to transfuse? (<i>Please state job title and, if doctor, give discipline and rank if possible</i>)
Q23. What was the pre-transfusion Hb in g/L? (up to 72 hours before first unit transfused)

Q24. How many units of red cells were given in all before the patient went to theatre?

Q25. Was the Hb recorded after each unit of red cells?	YesNo
Q26. Did the patient	YesNo
have acute	
coronary	
ischaemia*	
(*definition of ac	ute coronary ischaemia: STEMI (ST segment elevated myocardial infarction); NSTEMI (Non
ST segment eleva	tion myocardial infarction); Unstable angina within last 14 days)

Q27. If the patient was transfused at a pre-transfusion Hb of >70g/L (without acute coronary syndrome) or >80g/L (with acute coronary syndrome), please state reason for transfusion:

Q28 Was the patient on any of the following medications at any time in the month leading up to surgery *(that is up until the time of Nil by Mouth),* and if so were they stopped? If they were, give the date they were stopped. *If they were not on any of them, tick" None/ No record" and go to Q30.*

	Tick if patient on drug	Tick if stopped prior to surgery / or there is a note that patient was asked to stop	On what date was it stopped /or was the patient asked to stop?
Apixaban			
Dabigatran			
Rivaroxaban			
Warfarin			
Other oral anticoagulant (please state)			


Clopidogrel		
Prasugrel		
Ticagrelor		
Other antiplatelet agent (please state)		

None / No record of any of the above medication prior to surgery

Q29. If the patient was on clopidogrel, prasugrel or ticagrelor or other antiplatelet agent **and it was not stopped**, give details of the documented clinical reason for continuing it:

Use a code to tell us the reason for continuing: A = coronary artery stent within last 12 months, B = acute coronary syndrome, C = other, D = don't know. If you use code C , please provide brief details		
Clopidogrel		
Prasugrel		
Ticagrelor		
Other antiplatelet agent		

Q30. What was the pre-operative Hb taken closest before the date of surgery?



Q32. Was the patient on Warfarin pre-operatively?

Yes Now go to Q33	o Now go to Q35
Q33. What was the INR result taken cl	osest before the date of surgery?
Q34. What was the date of that INR ch	eck?

C: Patient Blood Management while in theatre and recovery

Q35. Was tranexamic acid used for this patient?

Yes Complete the table below, then go to Q36 No Now go to Q36

If used, write dose in relevant box	Before surgery started	During surgery	After surgery
Oral			
IV			
Intra-articular			

Q36. Was aprotonin used for this patient?

Yes *Now go to Q37*

No Now go to Q38

Q37. What was the dose used? (Please state in mls and not KIU) Dose

Q38. Were haemostatic agents or sealants used for this patient?

Yes *Now go to Q39*

No *Now go to Q40*

Q39. Which agents or sealants were used?

Q40. Was collection for intra-operative cell salvage (IOCS) commenced?

Yes Now go to Q41

No Now go to Q42

Q41. Which of these describes the outcome of using IOCS?

Collected but not reinfused due to insufficient volume

Collected and reinfused – (state volume reinfused)

mls

Q42. Why was cell salvage not commenced?
IOCS was not available on the day of surgery
Not worthwhile in this procedure as anticipated blood loss generally too low
Not considered in this procedure because of contaminated field
Not considered in this procedure because of sepsis
Not considered in this procedure because of malignancy
Other, please state:
Q43. Was near patient testing of haemostasis undertaken?
Yes Now go to Q44 No Now go to Q45
Q44. Which of these near patient testing options were undertaken? (tick as many as apply) TEG RoTEM Platelet function testing Activated Clotting Time Other, please state:

Questions 45 to 52 ask about allogeneic blood that was transfused in theatre or recovery, in other wordsintra-operative transfusion. If allogeneic blood was used, answer Yes to Q45 and continue throughto Q52. If allogeneic bloodwas not used, answer No to Q45 and go to Q53.

We ask you to give details of post -op cell salvage and post-op allogeneic transfusion in Section D

Q45. Was there any intra-operative transfusion with allogeneic red cells issued by the transfusion laboratory?

Yes Now go to Q46

No Now go to Q53

Q46. Who made the decision to transfuse? (*Please state job title and, if doctor, give discipline and rank if possible*)

Q47. Was the pre-transfusion Hb checked within 1 hour before transfusing the first unit?

Yes *Now go to Q48*

No Now go to Q50

Q48. How was the pre-transfusion Hb checked?

- Laboratory Hb from FBC sample
- Hb from blood gas analyser
- Hb from 'Masimo'
- Hb from Haemocue
- Other, please state

Q49. What was the first intra-operative pre-transfusion Hb?

12		

g/L

or 🗌 Not done

Reason for intra-operative transfusion:

Q50. Did the patient have active bleeding?

Yes Now complete the boxes below, then go to Q52

No *Now go to Q51*

Please state how the active bleeding was recorded in the notes: give estimated blood loss (EBL) and / or change in physiological parameters:

EBL (mls)

Change in parameters

Q51. The patient did not have active bleeding, so why were they transfused?

Q52. How many units of red cells were transfused intra-operatively?
On arrival in recovery:
Q53. Was an Hb taken on arrival in recovery?
Yes Now go to Q54 No Now go to Q55
Q54. What was the Hb taken on arrival in recovery? g/L
D: Post-operative Patient Blood Management <i>(when the patient had returned to the ward or had gone to</i> HDU or similar)
Q55. Was post-operative cell salvage used?
Yes Now go to Q56 No Now go to Q58
Q56. Which post-op cell salvage technique(s) was/were used:
 Reinfused shed blood Washed red cells Other (You do not need to gives us details of other techniques)
Q57. What was the total volume in mls of post-operative salvaged blood infused?
Q58. What was the first Hb taken on day 1? g/L or Not done (Day 1 is the next calendar day after surgery)
Q59. Did any of these complications of surgery occur? (Tick as many as apply)
No complications noted
Return to theatre VTE Wound infection Positive blood culture Other, please state:
Q60. Was the patient given post-operative iron?
Yes Now go to Q61 No Now go to Q62

Q61. Was it given orally IV (Tick one or both as applicable)


This is where you tell us about any allogeneic red cells that were transfused once the patient had left recovery. A transfusion episode is all units of red cells given against one prescription.

Q62. Was there transfusion on any of the first seven post-operative days? (i.e. Day 1 to day 7)

Yes *Now go to Q63*

No Now go to Q66

Q63. How many post-operative transfusion episodes were there? (A transfusion episode = any red cells transfused within a 24 hour period)



Q64. Did the patient have an adverse reaction to ANY transfusion?

Yes *Now go to Q65*

No Now go to Q66

Q65. What type of blood caused the reaction? 🗌 Autologous

Q65a. Please supply details:

Date	Was the transfusion Pre-op, Intra-op or Post-op?	SHOT category

Q66. Did the patient die during this admission?

Yes *Now go to Q67*

No Now go to Q68

Q67. What was the date of death?

Q68. What was the date of discharge?

Allogeneic

Q69. What was the Hb on or nearest to discharge / death? g/L Now go to Q70
or Not done Go to Episode 1 if there was post-operative transfusion with allogeneic blood
Q70. What was the date of the Hb test?
Episode 1
a) Date of transfusion
b) Time of transfusion
c) Who made the decision to transfuse?
d) What was the pre transfusion Hb (within 12 hours of transfusion)? g/L
e) How many units of red cells were given?
f) Was the Hb recorded after each unit of red cells? Yes No
g) Did the patient have acute coronary ischaemia? Yes No **Definition of acute coronary ischaemia: STEMI (ST segment elevated myocardial infarction), NSTEMI (Non ST segment elevation myocardial infarction) unstable angina) within last 14 days.
h) What was the reason for transfusion? Active bleeding *Active post-operative bleeding defined as bleeding causing systolic Hb <90mmHg, and or heart rate >110bpm, and or return to theatre because of bleeding and or activation of major haemorrhage pathway.
An Hb <70 g/L without acute coronary syndrome
An Hb <80 g/L with acute coronary syndrome
Other, please state

Episode 2

Episode 2	
i) Date of transfusion	

j) Time of transfusion

k) Who made the decision to transfuse?

I) What was the pre transfusion Hb (within 12 hours of transfusion)? g/L	
m) How many units of red cells were given?	
n) Was the Hb recorded after each unit of red cells?	
o) Did the patient have acute coronary ischaemia? **Definition of acute coronary ischaemia: STEMI (ST segment elevated myocardial infarction), NSTEMI (I ST segment elevation myocardial infarction) unstable angina) within last 14 days.	Von
 p) What was the reason for transfusion? Active bleeding *Active post-operative bleeding defined as bleeding causing systolic Hb <90mmHg, and or heart rate >110bpm, and or return to theatre because of bleeding and or activation of major haemorrhage pathwa 	у.
An Hb <70 g/L without acute coronary syndrome	
An Hb <80 g/L with acute coronary syndrome	
Other, please state	

Episode 3

q) Date of transfusion

r) Time of transfusion
s) Who made the decision to transfuse?
t) What was the pre transfusion Hb (within 12 hours of transfusion)?
u) How many units of red cells were given?
v) Was the Hb recorded after each unit of red cells?
w) Did the patient have acute coronary ischaemia? **Definition of acute coronary ischaemia: STEMI (ST segment elevated myocardial infarction), NSTEMI (Nor ST segment elevation myocardial infarction) unstable angina) within last 14 days.
 x) What was the reason for transfusion? Active bleeding *Active post-operative bleeding defined as bleeding causing systolic Hb <90mmHg, and or heart rate >110bpm, and or return to theatre because of bleeding and or activation of major haemorrhage pathway.
An Hb <70 g/L without acute coronary syndrome
An Hb <80 g/L with acute coronary syndrome
Other, please state
Episode 4

- y) Date of transfusion
- z) Time of transfusion

aa) Who made the decision to transfuse?
ab) What was the pre transfusion Hb (within 12 hours of transfusion)?
ac) How many units of red cells were given?
ad) Was the Hb recorded after each unit of red cells?
ae) Did the patient have acute coronary ischaemia? **Definition of acute coronary ischaemia: STEMI (ST segment elevated myocardial infarction), NSTEMI (Non ST segment elevation myocardial infarction) unstable angina) within last 14 days.
af) What was the reason for transfusion? Active bleeding *Active post-operative bleeding defined as bleeding causing systolic Hb <90mmHg, and or heart rate >110bpm, and or return to theatre because of bleeding and or activation of major haemorrhage pathway.
An Hb <70 g/L without acute coronary syndrome
An Hb <80 g/L with acute coronary syndrome
Other, please state
Episode 5
ag) Date of transfusion
ah) Time of transfusion
ai) Who made the decision to transfuse?

aj) What was the pre transfusion Hb (within 12 hours of transfusion)?
ak) How many units of red cells were given?
al) Was the Hb recorded after each unit of red cells?
am) Did the patient have acute coronary ischaemia? Yes No **Definition of acute coronary ischaemia: STEMI (ST segment elevated myocardial infarction), NSTEMI (Non ST segment elevation myocardial infarction) unstable angina) within last 14 days.
an) What was the reason for transfusion? Active bleeding *Active post-operative bleeding defined as bleeding causing systolic Hb <90mmHg, and or heart rate >110 bpm, and or return to theatre because of bleeding and or activation of major haemorrhage pathway.
An Hb <70 g/L without acute coronary syndrome
An Hb <80 g/L with acute coronary syndrome
Other, please state

If there were more than 5 episodes of post-operative allogeneic red cell transfusion in the 7 postoperative days, please contact us for advice on how to proceed.

END

List of participating sites

Airedale NHS Foundation Trust Altnagelvin Area Hospital Ashford and St Peters Hospitals NHS Foundation Trust **Barnet Hospital Barnsley Hospital NHS Foundation Trust Barts Health NHS Trust** Basildon and Thurrock University Hospitals NHS **Foundation Trust** Beaumont Hospital Belfast Health and Social Care Trust Betsi Cadwaladr University Health Board **Birmingham Heartlands Hospital Birmingham Women's NHS Foundation Trust** Blackpool Victoria Hospital **Bon Secours Hospital Cork Borders General Hospital** Bradford Teaching Hospitals NHS Foundation Trust Brighton and Sussex University Hospitals NHS Trust Calderdale and Huddersfield NHS Foundation Trust **Central Manchester University Hospitals NHS** Foundation Trust **Chase Farm Hospital** Chelsea and Westminster Hospital NHS Foundation Trust **Chesterfield Royal Hospital NHS Foundation Trust Colchester Hospital University NHS Foundation Trust Conquest Hospital** County Hospital (Stafford) Craigavon Area Hospital **Croydon Health Services NHS Trust Darent Valley Hospital Darlington Memorial Hospital Derby Hospitals NHS Foundation Trust Derriford Hospital** Doncaster and Bassetlaw Hospitals NHS Foundation Trust Doncaster and Bassetlaw Hospitals NHS Foundation Trust

Dorset County Hospital NHS Foundation Trust East and North Hertfordshire NHS Trust East Lancashire Hospitals NHS Trust Eastbourne Hospital Forth Valley Royal Hospital Frimley Park Hospital **Furness General Hospital Galway Clinic** Galway University Hospital Gateshead Health NHS Foundation Trust George Eliot Hospital NHS Trust **Gloucestershire Hospitals NHS Foundation Trust** Great Western Hospitals NHS Foundation Trust Guys and St Thomas' NHS Foundation Trust Hammersmith Hospital Hampshire Hospitals NHS Foundation Trust Harrogate and District NHS Foundation Trust HCA International Group Hospitals Hinchingbrooke Hospital Homerton University Hospital NHS Foundation Trust Hospital of St John & St Elizabeth Hull Royal Infirmary James Paget University Hospital Kent & Canterbury Hospital **Kettering General Hospital NHS Foundation Trust** King Edward VIIs Hospital Sister Agnes King's College Hospital NHS Foundation Trust King's Mill Hospital **Kingston Hospital** Lancashire Teaching Hospitals NHS Foundation Trust Liverpool Heart & Chest Hospital Liverpool Women's NHS Foundation Trust London North West Healthcare NHS Trust Maidstone Hospital Medway Maritime Hospital Mid Cheshire Hospitals NHS Foundation Trust Mid Essex Hospital Services NHS Trust

Milton Keynes NHS Foundation Trust Nevill Hall Hospital NHS Lothian Norfolk & Norwich University Hospital North Bristol NHS Trust North Cumbria University Hospitals NHS Trust North Middlesex University Hospital North Tees and Hartlepool NHS Foundation Trust Northern Devon Healthcare NHS Trust Northern Lincolnshire and Goole Hospitals NHS **Foundation Trust** Northumbria Healthcare NHS Foundation Trust Nottingham University Hospitals NHS Trust Nuffield Cheltenham Hospital Nuffield Orthopaedic Centre (NHSI) **Oswestry Orthopaedic Hospital** Our Lady's Hospital Navan **Oxford University Hospitals NHS Trust Papworth Hospital NHS Foundation Trust** Peterborough and Stamford Hospitals NHS **Foundation Trust Poole Hospital** Portsmouth Hospitals NHS Trust **Princess Alexandra Hospital** Queen Elizabeth Hospital Woolwich Queen Elizabeth The Queen Mother Hospital Queen's Hospital Burton Queen's Hospital Romford Ramsay Ashtead Hospital Ramsay Duchy Ramsay Euxton Hall Hospital Ramsay Fitzwilliam Hospital Ramsay Oaklands Hospital Ramsay Park Hill Hospital **Ramsay Springfield Hospital** Ramsay West Midlands **Royal Berkshire Hospital Royal Bolton Hospital** Royal Brompton and Harefield NHS Foundation Trust Royal Devon & Exeter Hospital

Royal Free Hospital Royal Gwent Hospital Royal Lancaster Infirmary Royal National Orthopaedic Hospital NHS Trust Royal Surrey Country Hospital Royal United Hospital Salford Royal NHS Foundation Trust Salisbury NHS Foundation Trust Sandwell and West Birmingham Hospitals NHS Trust Scarborough General Hospital Sheffield Teaching Hospitals NHS Foundation Trust Torbay and South Devon NHS Foundation Trust South Infirmary Victoria University Hospital Cork South Tees Hospitals NHS Foundation Trust South Tyneside NHS Foundation Trust South Warwickshire NHS Foundation Trust South West London Elective Orthopaedic Centre Southampton General Hospital Southend University Hospital Southport and Ormskirk Hospital NHS Trust Spire Alexandra Hospital Spire Bristol Hospital Spire Cambridge Lea Spire Clare Park Hospital Spire Gatwick Park Hospital Spire Harpenden Hospital Spire Hull & East Riding Hospital Spire Leicester Hospital Spire Little Aston Hospital Spire Murrayfield Hospital Wirral Spire Parkway Hospital Spire South Bank Hospital - Hospital Spire St Anthony's Hospital Spire Thames Valley Hospital Spire Washington Hospital Spire Wellesley Hospital Spire Yale Hospital St Mary's Hospital, Paddington St. George's University Hospitals NHS Foundation Trust

St. Vincent's University Hospital St. Woolos Hospital **Stockport NHS Foundation Trust** Sunderland Royal Hospital Surrey and Sussex Healthcare NHS Trust **Tameside Hospital NHS Foundation Trust Taunton & Somerset Hospital** The Dudley Group of Hospitals NHS Foundation Trust The Hillingdon Hospitals NHS Foundation Trust The Ipswich Hospital NHS Trust The Leeds Teaching Hospitals NHS Trust The Mid Yorkshire Hospitals NHS Trust The Montefiore Hospital The Newcastle upon Tyne Hospitals NHS Foundation Trust The Pennine Acute Hospitals NHS Trust The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust The Rotherham NHS Foundation Trust The Royal Bournemouth & Christchurch Hospitals NHS Foundation Trust The Royal Liverpool and Broadgreen University **Hospitals NHS Trust** The Royal Marsden NHS Foundation Trust The Royal Orthopaedic Hospital Birmingham The Royal Wolverhampton Hospitals NHS Trust The Shrewsbury and Telford Hospital NHS Trust The Ulster Hospital The York Hospital United Lincolnshire Hospitals NHS Trust University College London Hospitals NHS Foundation Trust

University Hospital Aintree University Hospital Coventry University Hospital Lewisham University Hospital Limerick University Hospital of North Durham University Hospital of South Manchester NHS F. Trust University Hospitals Birmingham NHS Foundation Trust University Hospitals Bristol NHS Foundation Trust University Hospitals of Leicester NHS Trust Walsall Healthcare NHS Trust Warrington and Halton Hospitals NHS Foundation Trust West Hertfordshire Hospitals NHS Trust West Middlesex University Hospital NHS Trust West Suffolk NHS Foundation Trust Western Sussex Hospitals NHS Foundation Trust Westmorland General Hospital Weston Area Health NHS Trust Wexham Park Hospital Whiston Hospital William Harvey Hospital Worcestershire Acute Hospitals NHS Trust Wrightington, Wigan and Leigh NHS Foundation Trust Wye Valley NHS Trust Yeovil District Hospital NHS Foundation Trust